Erich Mohr - Kintara Therapeutics Independent Director
Director
Dr. Erich Mohr, Ph.D. is Chairman of the Board of the Company. He has served as our Independent Chairman since July 7, 2017 and as independent director since March 31, 2015. Dr. Mohr has nearly two decades of biotechnology experience in executive leadership roles as cofounder, chief scientific officer, chief executive officer and board member. Dr. Mohr has overseen and participated in dozens of clinical development programs and regulatory advisory panels. He is currently Chairman, Chief Executive Officer and Founder of MedGenesis Therapeutix Inc., a privatelyheld biopharmaceutical company committed to developing and commercializing innovative therapeutics to provide lifeenhancing treatments to patients with serious neurologic diseases. Formerly, he was Chairman and Chief Executive Officer of CroMedica Global Inc., which merged with PRA International in 2002 to form one of the major contract research organizations in the world. In addition to his industry experience, Dr. Mohr has over 30 years of experience in experimental therapeutics of CNS disorders including eight years at the University of Ottawa, ultimately as a Professor of Medicine and Psychology. Dr. Mohr is the author of over 150 publications, books, book chapters and abstracts. Currently, he is the Chair of the Board of Governors of the University of Victoria, British Columbia, having previously served as a member and as Vice Chair. He earned his Masters of Science and Ph.D. in Neuropsychology at the University of Victoria, British Columbia, and his Bachelors of Arts in Psychology and dual Bachelors of Science in Chemistry and Biology from the University of the Pacific in Stockton, California. Dr. Mohrs scientific and business executive knowledge and experience qualify him to serve on our Board of Directors. since 2017.
| Age | 62 |
| Tenure | 7 years |
| Phone | 858-350-4364 |
| Web | http://www.delmarpharma.com |
Kintara Therapeutics Management Efficiency
The company has return on total asset (ROA) of (136.86) % which means that it has lost $136.86 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (316.72) %, meaning that it created substantial loss on money invested by shareholders. Kintara Therapeutics' management efficiency ratios could be used to measure how well Kintara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Karen Sheriff | BCE Inc | 63 | |
| Thomas Fitzpatrick | Iridium Communications | 66 | |
| Calin Rovinescu | BCE Inc | 65 | |
| Robert Simmonds | BCE Inc | 67 | |
| Cassandra Carr | MGIC Investment Corp | 73 | |
| Eric Olson | Iridium Communications | 66 | |
| Mark Zandi | MGIC Investment Corp | 61 | |
| Katherine Ong | Employers Holdings | 57 | |
| Jerry Lewin | Kandi Technologies Group | 60 | |
| James Kroner | Employers Holdings | 58 | |
| Liming Chen | Kandi Technologies Group | 78 | |
| Ian Greenberg | BCE Inc | 77 | |
| Kenneth Jastrow | MGIC Investment Corp | 72 | |
| Stanford Smith | Iridium Communications | 55 | |
| David Denison | BCE Inc | 68 | |
| Thomas Richards | BCE Inc | 65 | |
| Steven Pfeiffer | Iridium Communications | 71 | |
| Donald Nicolaisen | MGIC Investment Corp | 70 | |
| Sheila Murray | BCE Inc | 65 | |
| Monique Leroux | BCE Inc | 67 | |
| Barbara Higgins | Employers Holdings | 53 | |
Management Performance
| Return On Equity | -316.72 | |||
| Return On Asset | -136.86 |
Kintara Therapeutics Leadership Team
Elected by the shareholders, the Kintara Therapeutics' board of directors comprises two types of representatives: Kintara Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kintara. The board's role is to monitor Kintara Therapeutics' management team and ensure that shareholders' interests are well served. Kintara Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kintara Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scott Praill, CFO and Principal Accounting Officer | ||
| John Bell, Independent Director | ||
| William Garner, Director | ||
| Erich Mohr, Independent Director | ||
| Saiid Zarrabian, Director | ||
| Robert Toth, Director | ||
| Dennis Brown, Chief Scientific Officer, Director | ||
| Jeffrey Bacha, President CEO, Director | ||
| Lynda Cranston, Independent Director | ||
| Robert Hoffman, Independent Director | ||
| Napoleone Ferrara, Director |
Kintara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kintara Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -316.72 | |||
| Return On Asset | -136.86 | |||
| Current Valuation | 13.09 M | |||
| Shares Outstanding | 11.46 M | |||
| Shares Owned By Insiders | 1.44 % | |||
| Shares Owned By Institutions | 12.46 % | |||
| Number Of Shares Shorted | 246.63 K | |||
| Price To Earning | (1.68) X | |||
| Price To Book | 3.26 X | |||
| EBITDA | (8.26 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kintara Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kintara Therapeutics' short interest history, or implied volatility extrapolated from Kintara Therapeutics options trading.
Pair Trading with Kintara Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kintara Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kintara Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Netflix could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Netflix when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Netflix - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Netflix to buy it.
The correlation of Netflix is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Netflix moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Netflix moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Netflix can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Kintara Stock
If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |